Hemostemix Inc.
Hemostemix Inc. (HEM.V) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
hem.v · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Hemostemix Inc. (HEM.V) measures how much investors pay for each dollar of the company's trailing earnings. HEM.V's current PE ratio of N/A is calculated by dividing its stock price of $0.06 by its TTM earnings per share of -$0.03.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2012 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Hemostemix Inc.You HEM.V | $11M | N/A | — | -$0.03 |
 Britannia Life Sciences Inc. BLAB.CN | $14M | 1.65x | — | $0.05 |
 Rapid Dose Therapeutics Corp. DOSE.CN | $13M | N/A | — | -$0.04 |
 Pharmala Biotech Holdings Inc. MDMA.CN | $16M | N/A | — | -$0.02 |
 Marvel Biosciences Corp. MRVL.V | $14M | N/A | — | -$0.05 |
 Pangenomic Health Inc. NARA.CN | $5M | N/A | — | -$0.19 |
 PreveCeutical Medical Inc. PREV.CN | $9M | N/A | — | -$0.00 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.03 | — | |
2024-12-31 FY2024 | — | $-0.03 | — | |
2023-12-31 FY2023 | — | $-0.03 | — | |
2022-12-31 FY2022 | — | $-0.07 | — | |
2021-12-31 FY2021 | — | $-0.11 | — | |
2020-12-31 FY2020 | — | $-0.24 | — | |
2019-12-31 FY2019 | — | $-0.32 | — | |
2018-12-31 FY2018 | — | $-0.41 | — | |
2017-12-31 FY2017 | — | $-0.56 | — | |
2016-12-31 FY2016 | — | $-1.12 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Hemostemix Inc. (HEM.V) measures how much investors pay for each dollar of the company's trailing earnings. HEM.V's current PE ratio of N/A is calculated by dividing its stock price of $0.06 by its TTM earnings per share of -$0.03.
Frequently asked questions
HEM.V pe ratio · 6 questionsHEM.V's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.06 and TTM EPS of -$0.03. Data sourced from Financial Modeling Prep via HEM.V's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Hemostemix Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08